

Table 3.2
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for MRC Super Cohort Participants¹

Data as of: March 31, 2018; Events through March 31, 2018

Outcomes	Race/Ethnicity					
	American Indian/Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/Latina	White	Unknown
Number randomized	130	527	14618	6484	22030	385
Mean follow-up (months)	165.6	167.4	159.1	150.3	189.1	173.9
Cardiovascular						
CHD ²	11 (0.61%)	28 (0.38%)	966 (0.50%)	217 (0.27%)	2145 (0.62%)	32 (0.57%)
CHD death ³	7 (0.39%)	10 (0.14%)	497 (0.26%)	71 (0.09%)	851 (0.25%)	8 (0.14%)
Clinical MI	6 (0.33%)	22 (0.30%)	599 (0.31%)	168 (0.21%)	1534 (0.44%)	26 (0.47%)
Angina ⁴	7 (0.69%)	14 (0.34%)	548 (0.48%)	160 (0.33%)	884 (0.49%)	12 (0.40%)
CABG/PTCA	10 (0.56%)	23 (0.31%)	737 (0.38%)	264 (0.33%)	1894 (0.55%)	30 (0.54%)
Carotid artery disease	1 (0.06%)	4 (0.05%)	96 (0.05%)	22 (0.03%)	388 (0.11%)	3 (0.05%)
Congestive heart failure, WHI ⁴	3 (0.30%)	9 (0.22%)	477 (0.42%)	91 (0.19%)	655 (0.36%)	11 (0.37%)
Heart failure, UNC ⁵	10 (0.56%)	21 (0.29%)	770 (0.40%)	148 (0.18%)	1810 (0.53%)	22 (0.39%)
Stroke	13 (0.72%)	21 (0.29%)	824 (0.43%)	189 (0.23%)	1613 (0.46%)	25 (0.45%)
PVD	3 (0.17%)	7 (0.10%)	235 (0.12%)	27 (0.03%)	380 (0.11%)	4 (0.07%)
DVT	5 (0.28%)	4 (0.05%)	207 (0.11%)	37 (0.05%)	822 (0.24%)	6 (0.11%)
Pulmonary embolism	4 (0.22%)	2 (0.03%)	185 (0.10%)	20 (0.02%)	639 (0.18%)	11 (0.20%)
DVT/PE	8 (0.45%)	4 (0.05%)	317 (0.16%)	49 (0.06%)	1158 (0.33%)	14 (0.25%)
Coronary disease ⁶	24 (1.34%)	59 (0.80%)	2148 (1.11%)	547 (0.67%)	4392 (1.26%)	63 (1.13%)
Aortic aneurysm ⁷	0 (0.00%)	0 (0.00%)	18 (0.05%)	3 (0.02%)	36 (0.04%)	0 (0.00%)
Valvular heart disease ⁷	1 (0.27%)	3 (0.20%)	52 (0.14%)	28 (0.18%)	305 (0.38%)	5 (0.41%)
Total cardiovascular disease⁸	33 (1.84%)	83 (1.13%)	3018 (1.56%)	750 (0.92%)	6020 (1.73%)	81 (1.45%)
Cancer						
Breast cancer	8 (0.45%)	36 (0.49%)	920 (0.47%)	305 (0.38%)	1575 (0.45%)	23 (0.41%)
Invasive breast cancer	7 (0.39%)	28 (0.38%)	742 (0.38%)	248 (0.31%)	1305 (0.38%)	19 (0.34%)
Non-invasive breast cancer	1 (0.06%)	9 (0.12%)	200 (0.10%)	63 (0.08%)	294 (0.08%)	5 (0.09%)
Ovarian cancer	1 (0.06%)	3 (0.04%)	71 (0.04%)	37 (0.05%)	150 (0.04%)	4 (0.07%)
Endometrial cancer ⁹	1 (0.14%)	2 (0.04%)	89 (0.10%)	29 (0.06%)	197 (0.09%)	2 (0.06%)
Colorectal cancer	1 (0.06%)	17 (0.23%)	283 (0.15%)	76 (0.09%)	523 (0.15%)	9 (0.16%)
Other cancer ¹⁰	13 (0.72%)	47 (0.64%)	993 (0.51%)	335 (0.41%)	2562 (0.74%)	34 (0.61%)
Total cancer	23 (1.28%)	100 (1.36%)	2199 (1.13%)	734 (0.90%)	4648 (1.34%)	68 (1.22%)
Fractures						
Hip fracture	7 (0.39%)	10 (0.14%)	136 (0.07%)	70 (0.09%)	1220 (0.35%)	11 (0.20%)
Deaths						
Cardiovascular deaths	13 (0.72%)	18 (0.24%)	1015 (0.52%)	172 (0.21%)	1911 (0.55%)	17 (0.30%)
Cancer deaths	10 (0.56%)	36 (0.49%)	851 (0.44%)	264 (0.33%)	1735 (0.50%)	26 (0.47%)
Other known cause	12 (0.67%)	27 (0.37%)	717 (0.37%)	217 (0.27%)	1859 (0.54%)	23 (0.41%)
Unknown cause	0 (0.00%)	1 (0.01%)	29 (0.01%)	9 (0.01%)	40 (0.01%)	3 (0.05%)
Not yet adjudicated	2 (0.11%)	3 (0.04%)	107 (0.06%)	21 (0.03%)	266 (0.08%)	4 (0.07%)
Total Death	37 (2.06%)	85 (1.16%)	2719 (1.40%)	683 (0.84%)	5811 (1.67%)	73 (1.31%)
Death plus post-WHI deaths	46 (1.98%)	151 (1.58%)	4845 (1.85%)	1410 (1.17%)	8314 (2.08%)	122 (1.75%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2020.

³ "CHD death" includes definite and possible CHD death.

⁴ Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2020. Reported statistics represent experience during the original program.

⁵ Definite or possible decompensated heart failure adjudicated by UNC.

⁶ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure are not collected in the WHI Extension Studies 2005-2020.

⁷ Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2020.

⁸ Total CVD does not include aortic aneurysm or valvular heart disease.

⁹ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

¹⁰ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.